Nearly three million people worldwide live with multiple sclerosis, a chronic disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. In the United States alone, close to one million people are living with MS, according to a landmark study that found the figure was more than double what had previously been assumed. With no cure and treatments for progressive forms of the disease especially elusive, new approaches are drawing attention. Among them is a lead drug candidate from Quantum BioPharma (NASDAQ: QNTM) called Lucid-MS.
Lucid-MS is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2. Recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability in MS. By targeting the underlying mechanism of myelin damage, Quantum BioPharma aims to pursue a new path for better treatments. Global prevalence of MS rose from about 2.3 million people in 2013 to nearly 2.9 million in 2023, underscoring the growing need for effective therapies.
For investors and patients alike, the development of Lucid-MS represents a potential shift in how MS could be managed. If successful, it could address the unmet need for therapies that not only manage symptoms but also target the disease process itself. Quantum BioPharma’s efforts are part of a broader push to find solutions for a condition that affects millions. The company’s latest news and updates are available in its newsroom at https://ibn.fm/QNTM.
The announcement comes as the biotechnology sector continues to innovate in areas of high unmet need. BioMedWire, a communications platform focused on the latest developments in biotechnology, biomedical sciences, and life sciences, provides coverage of such advancements. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
While the path to approval is long and uncertain, the pursuit of new mechanisms like Lucid-MS highlights the urgency of finding better treatments for MS. With prevalence rising and no cure, innovations that target the disease’s root causes could have a significant impact on millions of lives. More details about Quantum BioPharma’s approach can be found in the full announcement at Read More>>.
